The Association for Molecular Pathology (AMP) provided comments at the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) meeting on October 8. AMP opposes the patenting of all naturally occurring genetic material and has signed on as a lead plaintiff in the ACLU case challenging Myriad Genetics' patents on the BRCA 1 and BRCA 2 genes. AMP thanked SACGHS for studying how both patents and restrictive licensing limit patient access and potentially reduce the quality of tests.
The Committee met to review their final draft report on gene patents and licensing practices, and recommended that the administration promote exemptions from liability for infringing on patent claims on genes for anyone making, using, ordering, offering for sale, or selling a test developed under the patent for patient care purposes or in the pursuit of research. They also called for enhanced transparency in licensing activities, public access to information about licensing actions and Federal adoption of efforts to promote broad licensing practices. AMP views this report as a call to action for policymakers to protect all patients from restricting patents and licensing practices.
AMP commends the SACGHS for taking a strong stance against business practices that harm patients, restrict innovation and reduce access to life saving tests. AMP President Dr. Jan Nowak commented, "This report is a milestone in our efforts to improve access to genetic tests. The threat of enforcement from a patent holder and the ensuing litigation costs has created a chilling effect on clinical laboratories making us reluctant to develop new tests that could directly benefit patients."